Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation

Fineline Cube Aug 4, 2026
Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer

Fineline Cube Aug 4, 2026
Company Drug

Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors

Fineline Cube Aug 4, 2026
Company

Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer to Drive Innovation

Fineline Cube Jun 16, 2023

China-based Everest Medicines (HKG: 1952) has announced the appointment of Dr. Mike Berry as Chief...

Company Legal / IP

AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa

Fineline Cube Jun 15, 2023

US-based AbbVie Inc., (NYSE: ABBV), the company behind the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor...

Company Drug

Janssen Submits Additional Indication Application to FDA for Carvykti in Multiple Myeloma

Fineline Cube Jun 15, 2023

The Janssen subsidiary of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an additional indication...

Company Drug

Dartsbio Pharmaceuticals and SIMM Receive NMPA Approval for ADC DS001 Clinical Trial

Fineline Cube Jun 15, 2023

Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has partnered with the Shanghai Institute of Materia Medica...

Company Deals

Hubei Guangji Pharmaceutical Partners with Jiangnan University for Green Manufacturing Innovation Lab

Fineline Cube Jun 15, 2023

China-based Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) has announced a strategic partnership with Jiangnan...

Company Drug

Hybio Pharmaceutical’s Semaglutide API Receives FDA Review Acceptance

Fineline Cube Jun 15, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the US Food and Drug...

Company Deals

YSB Inc. Lists on HKSE with HKD 363.6 Million IPO, Targeting Digital Pharma Services

Fineline Cube Jun 15, 2023

China-based ex-hospital digital pharmaceutical service platform YSB Inc. (HKG: 9885) has successfully made its initial...

Company Drug

Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09

Fineline Cube Jun 15, 2023

China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to...

Company Drug

Mabwell Bioscience’s IL-11 mAb 9MW3811 Receives US FDA Clinical Trial Approval

Fineline Cube Jun 15, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...

Policy / Regulatory

NHSA Report Highlights ‘Flying Inspections’ Impact on Medical Insurance Fund Use in 2022

Fineline Cube Jun 14, 2023

The National Healthcare Security Administration (NHSA) has released a report outlining the outcomes of ‘flying...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for HIF-2α Inhibitor HS-10516 Clinical Study

Fineline Cube Jun 14, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received approval...

Company Deals

Sino Biopharmaceutical Secures Exclusive Rights to Gmax Biopharm’s GMA106 in Greater China

Fineline Cube Jun 14, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) through its subsidiary Chia Tai Tianqing Pharmaceutical Co., Ltd, has...

Company

UIH Surgical to Invest RMB 2.5 Billion in Wuhan Medical Innovation and Robotics Base

Fineline Cube Jun 14, 2023

United Imaging Healthcare Technology Co., Ltd (UIH), through its subsidiary UIH Surgical, has announced plans...

Company Deals Medical Device

JJET’s IPO on STAR Market Accepted, Aims to Raise RMB 2.691 Billion for Medical Device Expansion

Fineline Cube Jun 14, 2023

China-based JJET has received acceptance for its Initial Public Offering (IPO) filing on the Shanghai...

Company Drug

Genevector Initiates Clinical Study for JWK001 in Neovascular Age-Related Macular Degeneration

Fineline Cube Jun 14, 2023

Chengdu-based adeno-associated virus (AAV) gene therapy developer, Genevector Biotechnology Co., Ltd., has announced the first...

Company Drug

Convalife Pharmaceuticals Gets NMPA Approval for Generic Neratinib Clinical Study

Fineline Cube Jun 14, 2023

Shanghai-based Convalife Pharmaceuticals has announced that it has received approval from the National Medical Products...

Company Drug

Croma-Pharma Initiates Phase III Clinical Trial in China for Hyaluronic Acid Dermal Filler

Fineline Cube Jun 13, 2023

Austria-based Croma-Pharma has revealed that the first patient is set to be enrolled in a...

Company Deals R&D

Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research

Fineline Cube Jun 13, 2023

Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement...

Company Deals

Apeloa Pharmaceutical Partners with Zelgen Biopharmaceuticals for CDMO Programs

Fineline Cube Jun 13, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Drug

Sinocelltech Group Receives NMPA Approval for Biosimilar Version of Humira

Fineline Cube Jun 13, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received market approval from...

Posts pagination

1 … 551 552 553 … 702

Recent updates

  • Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer
  • Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors
  • Shaanxi Micot Pharmaceutical Announces Positive Phase 2 Results for MT200605 in Acute Ischemic Stroke
  • CSPC Pharmaceutical Launches Phase Ib/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer
  • Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer

Company Drug

Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors

Company Drug

Shaanxi Micot Pharmaceutical Announces Positive Phase 2 Results for MT200605 in Acute Ischemic Stroke

Company Drug

CSPC Pharmaceutical Launches Phase Ib/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.